WO2022107027 - ADMINISTRATION OF STING AGONIST, CHECKPOINT INHIBITORS, AND RADIATION
National phase entry:
Publication Number
WO/2022/107027
Publication Date
27.05.2022
International Application No.
PCT/IB2021/060679
International Filing Date
18.11.2021
Title **
[English]
ADMINISTRATION OF STING AGONIST, CHECKPOINT INHIBITORS, AND RADIATION
[French]
ADMINISTRATION D'UN AGONISTE DE STING, D'INHIBITEURS DE POINT DE CONTRÔLE ET DE RAYONNEMENT
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi
Osaka 541-0045, JP
Inventors
SHAW, Michael H.
c/o Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, Massachusetts 02139, US
SATO, Yosuke
c/o Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi
Osaka 541-0045, JP
Priority Data
63/115,398
18.11.2020
US
63/140,125
21.01.2021
US
63/184,295
05.05.2021
US
63/275,480
04.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3166 | |
| EPO | Filing, Examination | 27828 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 671 | |
| USA | Filing, Examination | 11760 |
Total: 44013 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a STING (stimulator of interferon genes) agonist, such as Compound No. 14 as defined in the description, or a pharmaceutically acceptable salt thereof, in combination with one or more checkpoint inhibitors and radiation. Also provided are medicaments for use in treating cancer.[French]
La présente invention concerne des méthodes, des compositions pharmaceutiques et des kits pour le traitement du cancer chez des patients en ayant besoin. Les méthodes consistent à administrer à un patient en ayant besoin un agoniste de STING (stimulateur des gènes de l'interféron) tel que le composé n° 14 tel que défini dans la description, ou un sel pharmaceutiquement acceptable de celui-ci, en combinaison avec un ou plusieurs inhibiteurs de point de contrôle et un rayonnement. L'invention concerne également des médicaments destinés à être utilisés dans le traitement du cancer.